Introduction
============

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease caused by the progressive loss of motor neurons and denervation of muscle fibres, resulting in muscle weakness and paralysis. The disease has an incidence of 2.7 per 100,000 people in Europe ([@ddw190-B1]). In the absence of a medical cure, average life expectancy post-diagnosis is between 2 and 5 years. On average, 10% of ALS cases are familial, of which 20% are caused by mutations in superoxide dismutase 1 (*SOD1*) on the basis of which ALS mouse models have been developed. As disease progression is indistinguishable between familial and sporadic ALS, common disease mechanisms are expected. ALS pathophysiology is non-cell autonomous ([@ddw190-B2]), and increased expression of several cytokines is detected in both patients ([@ddw190-B3]) and rodent models of the disease ([@ddw190-B4]). Increasing inflammation in ALS model mice is detrimental to survival ([@ddw190-B5],[@ddw190-B6]), although inflammation is not hypothesized to be a primary cause of human ALS ([@ddw190-B7]).

Genome-wide association analysis linked the inositol 1,4,5-trisphosphate receptor 2 gene (*ITPR2*) to ALS and increased *ITPR2* gene expression was found in blood samples of sporadic ALS patients ([@ddw190-B8]). This genetic association was not replicated in other studies ([@ddw190-B9],[@ddw190-B10]). Although recent exome sequencing of case-unaffected--parents trios identified a *de novo* variant in *ITPR2* ([@ddw190-B11]), the potential role of this variant remains unclear. The higher *ITPR2* gene expression in ALS also remains intriguing due to the important role of the gene product of *ITPR2*, the inositol 1,4,5-trisphosphate receptor 2 (*IP~3~R2*), in calcium signalling. IP~3~Rs release calcium from the endoplasmic reticulum (ER) into the cytosol after binding of IP~3~ ([@ddw190-B12]). *IP~3~R2* has a high amino acid conservation ([@ddw190-B13],[@ddw190-B14]) and is expressed by different cell types, including astrocytes ([@ddw190-B15]), oligodendrocytes ([@ddw190-B18]), Schwann cells ([@ddw190-B19]), macrophages, neutrophils and mast cells ([@ddw190-B20]). It is also the most sensitive isoform of the IP~3~ receptors essential for ER calcium release in astrocytes ([@ddw190-B21]), affecting the plasticity or the baseline synaptic activity of hippocampal neurons ([@ddw190-B21]). *IP~3~R2* knockout mice do not have a distinct phenotype ([@ddw190-B24]).

Calcium signalling plays an important role in motor neurons and could explain the selective vulnerability of motor neurons as well as the therapeutic effect of the only registered drug for ALS (riluzole) ([@ddw190-B25]). By decreasing glutamate release, riluzole diminishes excitotoxicity, which is at least partially due to an increase in intracellular calcium. Apart from calcium influx due to the relatively high level of Ca^2+^-permeable AMPA receptors on motor neurons ([@ddw190-B26]), we previously showed that higher calcium release from intracellular stores by overexpression *IP~3~R2* in neurons has a negative effect on the disease process in ALS mice ([@ddw190-B27]). On the other hand, genetic removal of an enzyme responsible for IP~3~ formation, phospholipase C delta, prolongs survival of *SOD1^G93A^* mice ([@ddw190-B28]). Moreover, the calcium release systems in the ER play a crucial role in the ER-mitochondria calcium cycle of which a disturbance could lead to the increased ER stress response observed in ALS ([@ddw190-B29],[@ddw190-B30]).

To investigate the relevance of increased *ITPR2* expression in ALS patients, we studied the expression of *ITPR2* in *SOD1^G93A^* mice and in several other models of both chronic and acute neurodegeneration, as well as after induction of systemic inflammation. To evaluate the functional relevance of the observed increase in *ITPR2* expression, we genetically removed one or both *ITPR2* alleles from *SOD1^G93A^* mice and determined its effect on disease onset and survival. In addition, we characterized *IP~3~R2* knockout mice and discovered disturbances in innate immunity, as well as increased IFNγ and IL1α expression levels. Our data indicate that *IP~3~R2* has a novel anti-inflammatory function that may modify the ALS disease progression.

Results
=======

*IP~3~R2* expression is increased in neurodegenerative disease models and after LPS stimulation
-----------------------------------------------------------------------------------------------

To investigate the role of *ITPR2* in ALS, we assessed whether *ITPR2* gene expression was increased in a mouse model of ALS. We performed quantitative PCR (qPCR) on ventral spinal cords of control and *SOD1^G93A^* mice at different disease stages. A significant upregulation of *ITPR2* gene expression was detected in the ventral spinal cords of symptomatic and end stage *SOD1^G93A^* mice compared to non-transgenic and *SOD1^WT^* mice ([Fig. 1A](#ddw190-F1){ref-type="fig"}). This upregulation in the spinal cord of ALS mice was specific to *IP~3~R2*, as the other IP~3~R isoforms (*IP~3~R1* and *IP~3~R3*) did not increase during disease ([Supplementary Material, Fig. S1A--B](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)). We were unable to confirm these differences at the protein level due to the lack of specific *IP~3~R2* antibodies without cross reactivity to *IP~3~R1* and/or *IP~3~R3* on Western blot or immunohistochemistry. Figure 1.Relative *IP~3~R2* gene expression is increased in models of neurodegeneration and inflammation. (**A**) Relative gene expression of *IP~3~R2* assessed by qPCR on ventral spinal cords of non-transgenic (ntg; *n* = 6), SOD1^WT^ (wt; *n* = 6), pre-symptomatic *SOD1^G93A^* (pre-s; *n* = 6), symptomatic *SOD1^G93A^* (s; *n* = 5) and end stage *SOD1^G93A^* (es; *n* = 5) mice (ANOVA, Bonferroni post-hoc). (**B**) Relative *IP~3~R2* gene expression analysed in the lumbar spinal cord of severely affected EAE-mice (*n* = 3) and control mice (*n* = 6) by qPCR (unpaired *t-*test). (**C**) Relative *IP~3~R2* gene expression analysed in the penumbra zone of stroke in mice (*n* = 4) and a similar region in the contralateral side of the brain by qPCR (paired *t*-test). (**D**) Relative *IP~3~R2* gene expression in ventral spinal cord astrocytes *in vitro* by 24 h LPS application (*n* = 8) or vehicle (*n =* 8; unpaired *t*-test). (**E**) Relative *IP~3~R2* gene expression in murine macrophages (*n =* 4; Wilcoxon signed rank test compared to 1.0, two-tailed). The dotted line reflects the normalising vehicle condition set at 1. Mean ± standard deviation. \**P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001, \*\*\*\* *P* \< 0.0001.

To investigate whether the upregulation of *ITPR2* expression is unique for ALS, we determined *IP~3~R2* gene expression in other models of neurodegeneration, both chronic and acute and affecting either the spinal cord or brain. In a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE) characterized by pronounced inflammation at lesion sites, increased *IP~3~R2* gene expression was also detected by qPCR in the lumbar spinal cord of affected mice ([Fig. 1B](#ddw190-F1){ref-type="fig"}). This was also observed in an acute model of neurodegeneration, as increased *IP~3~R2* gene expression was detected in the penumbra of photothrombotic cortical stroke ([Fig. 1C](#ddw190-F1){ref-type="fig"}). To analyse whether the upregulation of the IP~3~R in the above conditions was specific to type 2 of the receptor, qPCR analysis of *IP~3~R1* and *IP~3~R3* was performed on the same tissues. There was no upregulation of *IP~3~R1* or *IP~3~R3* in EAE affected lumbar spinal cords ([Supplementary Material, Fig. S2A--B](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)) or in stroke penumbra ([Supplementary Material, Fig. S2C--D](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)), indicating that the upregulation is indeed IP~3~R isoform 2 specific.

To assess whether induction of inflammation also modulates *IP~3~R2* gene expression, we treated different cell types *in vitro* with lipopolysaccharide (LPS). Murine primary astrocytes and murine peritoneal macrophages dose-dependently increased *IP~3~R2* expression when treated with LPS ([Fig. 1D and E](#ddw190-F1){ref-type="fig"}). This effect seems also specific to *IP~3~R2*, as gene expression of *IP~3~R1* and *IP~3~R3* was not significantly increased by LPS in murine astrocytes ([Supplementary Material, Fig. S2E and F](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)). Altogether, these data indicate that *IP~3~R2* may play a role in inflammation.

Genetic ablation of *IP~3~R2* is detrimental in *SOD1^G93A^* mice
-----------------------------------------------------------------

To investigate the functional relevance of the *ITPR2* upregulation in ALS, we crossbred *IP~3~R2* knockout (*IP~3~R2*^-/-^) mice with *SOD1^G93A^* mice. We first analysed by qPCR the *IP~3~R2* expression in the ventral spinal cord of *IP~3~R2*^-/-^ mice. As expected, *IP~3~R2* gene expression was ablated in *IP~3~R2*^-/-^ mouse and was reduced by 50% in the *IP~3~R2*^+/-^ ventral spinal cord ([Fig. 2B](#ddw190-F2){ref-type="fig"}). There was no compensation by increased mRNA expression of *IP~3~R1* ([Fig. 2A](#ddw190-F2){ref-type="fig"}) or *IP~3~R3* ([Fig. 2C](#ddw190-F2){ref-type="fig"}). Figure 2.*IP~3~R2* knockout exacerbates disease in *SOD1^G93A^* mice. Relative gene expression of *IP~3~R1* (**A**), *IP~3~R2* (**B**) and *IP~3~R3* (**C**) assessed by qPCR in ventral spinal cords of *IP~3~R2*^+/+ ^(*n =* 6), *IP~3~R2*^+/-^ (*n =* 6) and *IP~3~R2*^-/-^ (*n =* 6) mice. (**D**) Early symptom onset as determined by the hanging wire test between *IP~3~R2*^+/+ ^*SOD1^G93A^* (*n =* 6; 129.7 ± 8.6 days), *IP~3~R2*^+/-^ *SOD1^G93A^* (*n =* 7; 126.8 ± 9.1 days) and *IP~3~R2*^-/-^ *SOD1^G93A^* mice (*n =* 7; 126.4 ± 8.1 days, Log-rank, *P =* 0.88). (**E**) Late symptom onset as determined by the rotarod test between *IP~3~R2*^+/+ ^*SOD1^G93A^* (*n =* 6; 141.2 ± 5.1 days), *IP~3~R2*^+/-^ *SOD1^G93A^* (*n =* 7; 142.6 ± 5.4 days) and *IP~3~R2*^-/-^ *SOD1^G93A^* mice (*n =* 7; 138.7 ± 6.0 days, Log-rank, *P =* 0.55). (**F**) Survival analysis by determining the age of end stage of *IP~3~R2*^+/+ ^*SOD1^G93A^* (*n =* 19; 170.7 ± 9.6 days), *IP~3~R2*^+/-^ *SOD1^G93A^* (n= 17; 162.8 ± 9.6 days) and *IP~3~R2*^-/-^ *SOD1^G93A^* (*n =* 18; 153.2 ± 12.5 days; Log-rank, *P* \< 0.0001). (**G-H**) Disease progression as measured by grip strength of *IP~3~R2*^+/+ ^*SOD1^G93A^* mice (*n =* 5), *IP~3~R2*^+/-^ *SOD1^G93A^* mice (*n =* 7), *IP~3~R2*^-/-^ *SOD1^G93A^* mice (*n =* 6) and *IP~3~R2*^-/-^ mice (*n =* 4) for the fore limbs (G) and all limbs (H). (**I**) Quantification of neurons from lumbar spinal cord in adult *IP~3~R2*^+/+ ^(*n =* 3)^,^ *IP~3~R2*^-/-^ (*n =* 3) and 145 day old *IP~3~R2*^+/+ ^*SOD1^G93A^* (*n =* 3) and *IP~3~R2*^-/-^ *SOD1^G93A^* mice (*n =* 2; 2-way ANOVA disease stage *P =* 0.0061). (**J**) The viability of murine motor neurons isolated from *IP~3~R2*^-/-^ (*n =* 4) and non-transgenic (*n =* 4) plated on non-transgenic rat astrocytic feeder layers in serum-enriched media. Mean ± standard deviation.

The genetic ablation of *IP~3~R2* in *SOD1^G93A^* did not affect significantly the age of disease onset between genotypes as assessed by the hanging wire test ([Fig. 2D](#ddw190-F2){ref-type="fig"}), nor by the rotarod ([Fig. 2E](#ddw190-F2){ref-type="fig"}). Remarkably, there was a considerable and dose-dependent effect on the survival of ALS mice ([Fig. 2F](#ddw190-F2){ref-type="fig"}). This dose-dependency was consistent with the 50% expression of *IP~3~R2* in *IP~3~R2*^+/-^ ventral spinal cords compared to *IP~3~R2*^+/+ ^mice ([Fig. 2B](#ddw190-F2){ref-type="fig"}). The detrimental effect of *IP~3~R2* knockdown on disease progression was also shown in the decreased levels of relative grip strength between genotypes for the fore paws ([Fig. 2G](#ddw190-F2){ref-type="fig"}) and all paws ([Fig. 2H](#ddw190-F2){ref-type="fig"}). The number of motor neurons in the ventral horn of the lumbar spinal cord is lower in *IP~3~R2*^-/-^ *SOD1^G93A^* mice than in *IP~3~R2*^+/+ ^*SOD1^G93A^* mice at 145 days of age ([Fig. 2I](#ddw190-F2){ref-type="fig"}), as expected due to increased disease severity in *IP~3~R2*^-/-^ *SOD1^G93A^* mice at this age. The difference in survival is not likely due to a higher intrinsic vulnerability of *IP~3~R2*^-/-^ neurons, as their basal survival *in vitro* is not different compared to non-transgenic motor neurons ([Fig. 2J](#ddw190-F2){ref-type="fig"}). In addition, astrogliosis and microgliosis of the ventral horn of the lumbar spinal cord of *IP~3~R2*^+/+ ^*SOD1^G93A^* and *IP~3~R2*^-/-^ *SOD1^G93A^* mice seemed comparable at the end stage ([Supplementary Material, Fig. S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)). Altogether, our data show that genetic ablation of *IP~3~R2* is detrimental for motor neuron survival in *SOD1^G93A^* mice.

*IP~3~R2* knockout mice have increased inflammatory potential
-------------------------------------------------------------

In view of the effect of inflammation on *IP~3~R2* expression ([Fig. 1](#ddw190-F1){ref-type="fig"}) and to understand the mechanism responsible for the more rapid disease progression in *IP~3~R2*^-/-^ *SOD1^G93A^* mice, we investigated the relative contribution of immune cells in adult *IP~3~R2*^+/+ ^and *IP~3~R2*^-/-^ mice by flow cytometry. Within the adaptive immune system, there was no difference in the relative number or activation status of B cells or T cells ([Supplementary Material, Fig. S4A--D](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)). By contrast, large changes were observed in the myeloid populations. The relative number of Ly6C^hi^ monocytes was increased in both the spleen and blood of *IP~3~R2*^-/-^ mice ([Fig. 3A and B](#ddw190-F3){ref-type="fig"}). This effect was also observed with LyC6^lo^ monocytes in *IP~3~R2*^-/-^ mice, in both the spleen and blood ([Fig. 3C and D](#ddw190-F3){ref-type="fig"}). Neutrophils and dendritic cells were present in normal proportions ([Supplementary Material, Fig. S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1)). These data imply that there is an increased potential for systemic innate inflammation in the *IP~3~R2*^-/-^ mouse. Figure 3.Relative amounts of Ly6C^hi^ and Ly6C^lo^ monocytes as determined by FACS in adult *IP~3~R2*^+/+ ^and *IP~3~R2*^-/-^ mice. (**A**) Relative amount of Ly6C^hi^ monocytes in the spleen of *IP~3~R2*^+/+ ^(*n =* 7) and *IP~3~R2*^-/-^ mice (*n =* 8; unpaired *t*-test). (**B**) Relative amount of of Ly6C^hi^ monocytes in blood of *IP~3~R2*^+/+ ^(*n =* 7) and *IP~3~R2*^-/-^ mice (*n =* 8; unpaired *t*-test). (**C**) Relative amount of Ly6C^lo^ monocytes in spleen of *IP~3~R2*^+/+ ^(*n =* 6) and *IP~3~R2*^-/-^ mice (*n =* 8; unpaired *t*-test). (**D**) Relative amount of Ly6C^lo^ monocytes in blood of *IP~3~R2*^+/+ ^(*n =* 6) and *IP~3~R2*^-/-^ mice (*n =* 8; unpaired *t*-test). (**E**) Level of IFNγ in the serum of *IP3R2*^+/+^ mice (*n =* 14) and *IP3R2*-/- mice (*n =* 14; Mann-Whitney). (**F**) Level of IL-6 in the serum of *IP~3~R2*^+/+ ^mice (*n =* 14) and *IP~3~R2*^-/-^ mice (*n =* 14; Mann-Whitney). (**G**) Relative IL-6 gene expression assessed by qPCR in ventral spinal cords of *IP~3~R2*^+/+ ^(*n =* 6), *IP~3~R2*^+/-^ (*n =* 5) and *IP~3~R2*^-/-^ (*n =* 5) mice (ANOVA, Bonferroni correction for multiple testing). (**H**) Relative IL1α gene expression of embryonic ventral spinal cord astrocytes from *IP~3~R2*^+/+ ^(*n =* 2) and *IP~3~R2*^-/-^ (*n =* 2) mice treated with LPS (unpaired *t*-test). (**I**) Relative IL1α gene expression of the stroke zone, penumbra and contralateral side 7 days after photothrombotic stroke in *IP~3~R2*^+/+ ^(*n =* 5) and *IP~3~R2*^-/-^ mice (*n =* 3; 3 unpaired *t*-tests). Mean ± standard deviation. \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001.

To study the presence of systemic inflammation, we assessed interferon gamma (IFNγ) and interleukin 6 (IL6) in the serum of adult *IP~3~R2*^+/+ ^and *IP~3~R2*^-/-^ mice. IFNγ levels were increased in the serum of unchallenged *IP~3~R2*^-/-^ mice ([Fig. 3E](#ddw190-F3){ref-type="fig"}) and a similar trend was observed for IL6 ([Fig. 3F](#ddw190-F3){ref-type="fig"}). A (dose-dependent) role for IL-6 in the ventral spinal cord of *IP~3~R2*^+/+^, *IP~3~R2*^+/-^ and *IP~3~R2*^-/-^ mice is detected by qPCR analysis ([Fig. 3G](#ddw190-F3){ref-type="fig"}). To determine the potential role of *IP~3~R2* in induced neuroinflammation, we assessed the expression of the pro-inflammatory cytokine IL1α *in vitro* in embryonic ventral spinal cord astrocytes when treated with LPS. Here, we detected an increase of IL1α with decreasing copies of *IP~3~R2* ([Fig. 3H](#ddw190-F3){ref-type="fig"}). This is in accordance with our observations *in vivo* upon photothrombotic stroke, where the penumbra and stroke zone of *IP~3~R2*^-/-^ mice has increased gene expression of *IL1α* ([Fig. 3I](#ddw190-F3){ref-type="fig"}). Together, these data imply that genetic ablation of *IP~3~R2* causes increased propensity to inflammation, which may infer an exacerbated disease progression in *SOD1^G93A^* mice ([Fig. 2F](#ddw190-F2){ref-type="fig"}).

Discussion
==========

In this study, we show that the *ITPR2* gene expression is significantly upregulated in ALS and in other models of neurodegeneration, as well as after induction of inflammation. This upregulation of *ITPR2* expression may be a compensatory protective response in ALS, as genetic deletion of *IP~3~R2* exacerbates ALS disease progression in *SOD1^G93A^* mice and decreases survival dose-dependently. At first sight, this negative effect of *IP~3~R2* deletion is contra intuitive as it results in motor neurons in a lower intracellular calcium concentration in response to IP~3~-inducing agents. This could theoretically result in a higher resistance to excitotoxic damage as we have shown before that expression of more *IP~3~R2* in neurons has a negative effect ([@ddw190-B27]), while genetic ablation of an enzyme involved in the production of IP~3~ has a beneficial effect on the survival of *SOD1^G93A^* mice ([@ddw190-B28]). In addition, a lower number of IP~3~Rs in the ER could counteract the calcium depletion of this organelle. This will have a positive effect on the ER stress and protein misfolding that are the consequences of disturbances in the ER-mitochondria calcium cycle observed in motor neurons ([@ddw190-B29],[@ddw190-B30]). However, *IP~3~R2* is not only expressed in (motor) neurons. On the contrary, *IP~3~R2* is an important isoform in a number of non-neuronal cells ([@ddw190-B15]). As a consequence, the potential beneficial effect of removing *IP~3~R2* in motor neurons seems to be outnumbered by the negative effect of *IP~3~R2* removal in the other cell types.

As a consequence, we hypothesize that the negative effect of *IP~3~R2* expression on motor neurons is due to the loss of anti-inflammatory function exerted by *IP~3~R2* when it is genetically ablated from all cell types. That inflammation harbours a negative effect on survival of ALS mice has been shown previously by increasing inflammation by LPS injections ([@ddw190-B6]) and M-CSF administration ([@ddw190-B5]). The role of *IP~3~R2* in this process is new and unexpected. However, inflammation is also observed in *IP~3~R2* and *IP~3~R3* double knockouts in olfactory endothelium and lacrimal glands as increased levels of TNFα, MIP-2 and IL-6 gene expression are detected ([@ddw190-B31]). These double knockouts show defects in the function of secretory epithelial cells ([@ddw190-B24],[@ddw190-B31]), while *IP~3~R1* and *IP~3~R2* double knockout results in perturbations of cardiogenesis causing embryonic death ([@ddw190-B32]). For a long time, it was supposed that genetic ablation of solely *IP~3~R2* has no effect. Recently, a reduction in sweat production was reported ([@ddw190-B33]). Our data indicate that the inflammatory potential is also affected.

These data are in line with the hypothesis that the upregulation of *IP~3~R2* during inflammation is an inherent mechanism of the cell to reduce production of pro-inflammatory cytokines, by increasing intracellular calcium to block MAPK activation. *IP~3~R2* is particularly useful in this context as it is the most sensitive receptor subtype to IP~3~. Our study demonstrates that upregulation of *ITPR2* occurs in primary murine astrocytes and murine macrophages upon inflammation. Although an increase in *ITPR2* gene expression *in vivo* may be explained by infiltrating cell types rich in *ITPR2* expression, *in vitro* work with non-proliferating astrocytes in culture demonstrates that *ITPR2* expression can be increased per cell post-stimulation. Furthermore, *ITPR2* upregulation is also observed in HUVEC and epithelial cells after stimulation with anti-inflammatory treatment with Serp-1, which may explain in part the anti-inflammatory mechanism of Serp-1 ([@ddw190-B34]).

One possible pathway in which *IP~3~R2* could play a role in inflammation is linked to the stimulation of metabotropic glutamate receptors (mGluRs). This activates phospholipase C (PLC) to hydrolyse phosphatidylinositol 4,5-bisphosphate (PIP~2~) into diacylglycerol (DAG) and IP~3~. The latter activates IP~3~ receptors that allow ER calcium release. This higher cytoplasmic calcium concentration could block the activation of MAPK and cytokine/chemokine transcription. Interestingly, there are multiple mGluRs expressed by glia and activation of some of these may be anti-inflammatory. A role of mGluRs in neuroinflammation has been shown in cultured microglia in which activation of mGluR5 inhibits inflammation and neurotoxicity ([@ddw190-B35]). An upregulation of mGluRs is found on astrocytes in both ALS ([@ddw190-B36],[@ddw190-B37]) and MS patients ([@ddw190-B38]) and is correlated to glial fibrillary acidic protein (GFAP) expression ([@ddw190-B36]). It was also shown that an increase in IP~3~ formation and intracellular calcium concentration occurs in reactive cells, including astrocytes, in culture ([@ddw190-B39]) and this is inhibited by blocking PLC ([@ddw190-B40]). Genetically ablating *IP~3~R2* could result in a disinhibition of MAPK activation that increases cytokine/chemokine transcription, as intracellular calcium blocks MAPK activation ([@ddw190-B42],[@ddw190-B43]). Furthermore, pharmacological approaches have shown that inhibition of PLC or IP~3~ receptors or intracellular calcium chelation with BAPTA-AM increase the production of cytokines/chemokines in a variety of cell types including microglia ([@ddw190-B35],[@ddw190-B44]), oligodendrocytes ([@ddw190-B45]), hematopoietic stem cells/progenitor cells ([@ddw190-B42]), monocytes/alveolar macrophages ([@ddw190-B46]), neutrophils ([@ddw190-B47]) and vascular smooth muscle cells ([@ddw190-B48]). Interestingly, this process has not yet been associated with *IP~3~R2*.

In conclusion, we report a novel role of *ITPR2* in inflammation and a detrimental effect of genetic ablation of *ITPR2* in ALS. Altogether, our data suggest that this anti-inflammatory function of *ITPR2* may be effectively targetable in a number of cell types and (inflammatory) disorders, including ALS.

Materials and Methods
=====================

Animal studies
--------------

*IP~3~R2* knockout mice, described previously ([@ddw190-B24]), were intercrossed with high-copy number *SOD1^G93A^* (The Jackson Laboratory, Bar Harbor, USA). Human wild-type SOD1 overexpressing mice (*SOD1^WT^)* were obtained from The Jackson Laboratory for use as controls. All mice were on a C57BL/6 background. *IP~3~R2* knockout mice, *SOD1^G93A^* mice and *SOD1^WT^* mice were housed in standard conditions in the conventional housing facility of the University of Leuven with food and water *ad libitum*. Experiments performed at the University of Leuven were performed according to the guidelines of the University of Leuven and have received ethical committee approval (project codes 143/2008, 150/2009, 158/2009, 020/2010, 085/2011). Experiments performed at the Vrije Universiteit Brussel, were approved by the Ethical Committee for Animal Experiments (ECAE) at the Vrije Universiteit Brussel (project number 11-220-13), and all animal experiments met the standards required by the Belgian Council for Laboratory Animal Science (BCLAS) guidelines.

Motor testing and determination of survival
-------------------------------------------

The hanging wire test was used to determine early disease onset by assessing the ability of the mice to hold their own weight for 60 s, as previously described ([@ddw190-B49]). Briefly, we placed a mouse on a wire grid and turned it over while the mouse was holding its own body weight upside-down. If a mouse failed (dropped from the grid before 60 s) and in consecutive trials could not hold its own weight for 60 s, it was defined as symptomatic. The rotarod (Ugo Basile, Varese, Italy) is used to determine late stage disease onset. After training and consistent baseline measurements (5 measurements of maximal scores of 300 s on different days), mice are provided with three trials of 300 s. The average of the 3 trials per mouse is calculated (the length of time they remain on the rod) and symptom onset is defined as the first measurement when the average is less than 60 s and never increases above again. Grip strength measurements were performed with a dynamometer (Chatillon, Largo, FL, USA) every 5 days from 80 days of age onwards at which grip strength was determined with the mice holding a bar (fore limbs only) or when placed on a small grid (all limbs). Relative grip strength was determined per mouse by normalising the absolute grip strength (N) values to the average for each mouse from day 90 to day 105. End stage was determined when mice were unable to rear themselves within 30 s when placed on their back (also described as survival). Extra attention was paid to assess mice in comparison to their littermate controls.

Chronic progressive, experimental autoimmune encephalomyelitis
--------------------------------------------------------------

Experimental autoimmune encephalomyelitis **(**EAE) was induced by injecting C57BL/6 mice subcutaneously with 100 µg MOG peptide (Eurogentec, Fremont, CA, USA) and 400 µg mycobacterium butyricum (Difco, Becton Dickinson, Franklin Lakes, USA) in complete Freund\'s adjuvant (CFA) at three sites in the back. Mice received 400 ng Bordetella pertussis toxin (Calbiochem, Darmstadt, Germany) in NaCl 0.9% intraperitoneally (IP) at the time of immunization and 48 h later to disrupt the blood-brain barrier and lumbar spinal cord tissue was collected at 18 weeks.

Photothrombotic cortical stroke
-------------------------------

Focal cortical ischemia was induced in female C57BL/6J mice aged at least 3 months by photothrombosis, as previously described ([@ddw190-B50]). Mice were anesthetized with 2.5% isoflurane (Halocarbon, New Jersey, USA) in an oxygen/air mixture and rectal temperature during the surgical procedure was maintained at 37 ± 0.5 °C with a heating plate (TCAT-2LV Controller, Physitemp instruments, New Jersey, USA). After fixation in a stereotactic frame (David Kopf Instruments, Bilaney, Germany) the skull was exposed by a midline incision in the skin. Rose Bengal (Sigma, ST. Louis, MO, USA), 0.1 ml with a concentration of 3 mg/ml in normal saline, was infused by tail vein injection. For illumination, a laser beam of wavelength 565 nm (L4887-13, Hamamatsu Photonics, Japan) with a aperture of 1.8 mm was focused 0.5 mm anterior and 1.8 mm right of the bregma. The brain was illuminated immediately after Rose Bengal injection during 5 min through the intact skull. Seven days after stroke mice were perfused with PBS and the brain was dissected for mRNA extraction of the following regions: stroke zone, peri-infarct area, ipsilateral and contralateral cortex.

Quantitative PCR analysis
-------------------------

Isolation of mRNA from ventral spinal cord occurred by the TriPure (Roche, Basel, Switzerland) method and reverse transcriptase PCR with random hexamers (Life Technologies, Carlsbad, USA) and M-MLV (Invitrogen, Life Technologies). Quantitative Real-Time PCR (qPCR) analysis was performed with the StepOnePlus (Life Technologies) with TaqMan Universal PCR Master Mix (Life Technologies). All murine analyses were confirmed by at least two housekeeping genes. Assays were purchased from Life Technologies and IDT DNA and the signal quantified with the ΔΔCT method.

Protein levels determination
----------------------------

Serum was collected from mice directly after euthanization and approx. 100 µl shipped frozen to Aushon Biosystems (Billerica, MA, USA) for multiplexed SearchLight immunoassays. Data were analysed by an investigator blinded to the genotypes of the samples tested.

(Motor) neuron quantification
-----------------------------

To visualize neurons, Nissl staining was performed on 4% formaldehyde-fixed spinal cord sections. Sections were briefly immersed in a cresyl violet solution and subsequently in a 70% ethanol with 10% acetic acid. Slides were dehydrated by an increased ethanol concentration series and mounted with PerTex® (Histolab AB, Goteborg, Sweden). Images were collected by Zeiss Axio Imager M1 microscope (Carl Zeiss AG, Jena, Germany) with AxioCam Mrc5 camera (Carl Zeiss AG). The number of (motor) neurons was quantified by measurement of the soma area as visualized by cresyl violet staining in ImageJ (National Institute for Health) on multiple 40 µm thick sections in the ventral horn of the lumbar spinal cord. Characterization of motor neurons occurred as previously ([@ddw190-B51]) on at least five ventral horns of the lumbar spinal cord of 2--3 mice per group.

Immunohistochemistry
--------------------

Mice were transcardially perfused with phosphate buffered saline (PBS) and subsequently with 4% formaldehyde. Spinal cords were post-fixed with 4% formaldehyde overnight at 4 °C and transferred to 30% sucrose for an additional night. After snap freezing, tissue was sectioned by cryostat at 40 μm thickness and stained with antibodies against glial fibrillary acidic protein (GFAP, Santa Cruz Biotechnology, Santa Cruz, USA) and Iba1 (Wako, Japan). Secondary antibodies for immunofluorescence include Alexa-555 and Alexa-488 (Invitrogen). Vectashield with DAPI (Vector, Burlingame, CA) was used for mounting spinal cord sections. Images were collected by Zeiss Axio Imager M1 microscope (Carl Zeiss AG) with AxioCam Mrc5 camera (Carl Zeiss AG).

LPS treatment *in vitro*
------------------------

Primary cultures of neurons and astrocytic feeder layers were isolated on E13.5 as previously described ([@ddw190-B26]). Astrocytes from each embryo were divided over two wells on a 12-well plate and were allowed to grow until each well was fully covered. They were subsequently treated with arabinofuranosyl cytidine (VWR International, Leuven, Belgium) for at least 24 h to halt proliferation of the astrocytes and remove any other cell types present. Thereafter the medium was replaced for 24 h with media without penicillin and streptomycin (Invitrogen), collected and replaced with penicillin and streptomycin free media containing either 1 µg/ml of LPS or vehicle (H~2~0). Cells were lysed and mRNA preserved. The mRNA extraction occurred by the TriPure method and was purified with the RNeasy Qiagen kit according to the manufacturer's guidelines.

Thioglycolate-elicited peritoneal macrophages (thio-PEM) were obtained from non-transgenic C57BL/6-mice by IP injection of 3 ml thioglycolate (bioMérieux, Marcy l\'Etoile France). At day 4, mice were killed, followed by a peritoneal lavage with 10 ml PBS/10% sucrose. Extracted cells were counted and seeded in 6-well culture plates (Falcon, Becton Dickinson) at a concentration of 5 × 10^6^ cells/well. After 3 h incubation at 37° C and 5% CO~2~, non-adherent cells were washed away with PBS and plastic-adherent peritoneal macrophages were used for analysis. Thio-PEM were subjected to stimulation by 1 ng/ml or 100 ng/ml bacterial LPS (055:B5, Sigma). After 24 h of incubation at 37 °C and 5% CO~2~, RNA was extracted from each condition by TRIzol® Reagent (Invitrogen), and cDNA was synthesized. This cDNA was then used for quantitative PCR. Correct stimulation of the macrophages was confirmed by verifying the gene expression profile of inducible nitric oxide synthase (iNOS).

Fluorescent cytometry analysis
------------------------------

Single-cell suspensions were prepared from spleen and blood. Erythrocytes were depleted by lysis with NH~4~Cl~2~ solution. Peritoneal fluid was collected after lavage with cold and sterile PBS. Murine cells were harvested and cultured in Roswell Park Memorial Institute (RPMI) media with 10% foetal calf serum (FCS) plus supplement (glutamine, 2-mercaptoethanol, penicillin and streptomycin, and 10 mM HEPES). For cell-surface staining, 2--3 × 10^6^ cells per sample were incubated with various antibodies in staining buffer (PBS and 3% FCS) for 20 min at 4 °C. After 4 h of incubation in media with PMA (50 ng/ml) and ionomycin (500 ng/ml) intracellular cytokine staining was performed according to the manufacturer's guidelines for the BD Biosciences-Pharmingen Fixation/Permeabilization Solution Kit. Anti-murine antibodies included B220 (RA3-6B2), CD4 (GK1.5), CD8 (53-6.7), CD69 (H1.2F3), CD62L (MEL-14), CD44 (IM7), Gr-1 (RB6-8C5), CD11b (M1/70), CD11c (N418), F4/80 (BM8), Ly6C (HK1.4), MHCII (M5/114.15.2) and IFNγ (XMG1.2) all from eBioscience (San Diego, USA). Data were acquired on a Canto I flow cytometer (BD Biosciences, New Jersey, USA) and analysed using FlowJo for Mac version 9.2 (Tree Star Inc., Ashland, USA).

Statistical analysis
--------------------

Analysis was performed with the statistical software package Prism Origin. Survival and disease onset was analysed by Log-Rank. Multiple group analyses were performed by ANOVA followed by Bonferroni post hoc analysis. Differences over 2 groups were analysed by Student's *t*-test and the Mann-Whitney test or Wilcoxon signed rank test, as described, when a non-normal distribution of the data is assumed. Significance was assumed at *P* \< 0.05. Graphs represent the mean ± standard deviation.

Supplementary Material
======================

[Supplementary Material](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddw190/-/DC1) is available at *HMG* online.
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